• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

Media

Author
Posted by Author
December 13, 2021

A PATIENT'S Q&A

A PATIENT'S JOURNEY

Read More
Author
Posted by Author
December 13, 2021
Author
Posted by Author
October 25, 2021

W5: Harnessing the Power of Psychedelic Drug Therapy

A W5 investigation into an unconventional treatment for severe depression and PTSD that involves the drug ketamine.

Read More
Author
Posted by Author
October 22, 2021

Braxia Scientific Featured in National News; W5

Braxia Scientific Featured in National News, W5 Canada’s Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses TORONTO, ONTARIO October 22, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders. Braxia Scientific CEO Dr. Roger McIntyre will be featured on CTV’s W5, Canada’s most-watched current affairs and documentary program. The episode, entitled “Psychedelic Healing,” will air on Saturday, October 23, 2021, at 7 p.m. Eastern Standard Time (EST). Braxia Scientific and the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned subsidiary, are also highlighted in a recent article by Toronto Life, a monthly...

Read More
Author
Posted by Author
July 4, 2021

Quebec Curfew May Increase Feelings of Loneliness: Psychiatrist

TORONTO -- Sparked by an explosion of COVID-19 cases, Quebec’s month-long curfew could increase people’s feelings of loneliness, one expert warned, urging people to maintain personal connections and physical activity. “People are getting fed up with the uncertainty.” Roger McIntyre, a psychiatry and pharmacology professor from the University of Toronto, told CTV News Channel on Sunday. McIntyre understands how maddening it must be for Quebecers to contend with yet another measure when they are already facing economic strife under COVID-19 public health restrictions.  

Read More
Author
Posted by Author
July 4, 2021

‘Loneliness pandemic’: Work from home during COVID-19 takes mental toll on Canadians

“Working from home for many people in our society is a risk for further alienation and feeling very lonely and distant,” said Dr. Roger McIntyre”

Read More
September 12, 2022

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

TORONTO, ONTARIO September 12, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida.  KetaMD onboarded new patients and completed initial ketamine treatments. Eligible patients, as determined by one of KetaMD’s licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their home. KetaMD, Inc. (“KetaMD”), a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD). In multiple studies, ketamine...

September 12, 2022

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

TORONTO, ONTARIO September 9, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022. CEO Dr. Roger McIntyre will present virtually during the conference providing a update on its recently acquired U.S. based telemedicine business, KetaMD, as well as its progress expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors. The on-demand session will be available at 7:00 a.m. ET Monday September 12, 2022. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright.   About Braxia...

August 29, 2022

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

TORONTO, ONTARIO August 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the first quarter ended June 30, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. “We are proud to have launched KetaMD in the U.S. so that we can begin addressing the needs of millions lacking access to innovative treatments for mental health disorders such as depression, anxiety, bipolar disorder and post-traumatic stress disorder (PTSD),” said Dr. Roger McIntyre, CEO, Braxia...

August 3, 2022

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with Plans to Expand Across the U.S.

TORONTO, ONTARIO,  Aug. 3, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. ("KetaMD") (the "Transaction"). KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments. KetaMD Logo (CNW Group/Braxia Scientific Corp.) KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression. KetaMD's integration of ketamine and telemedicine is guided by best practices...

July 29, 2022

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results

Achieved Health Canada Special Access Program approval to provide psilocybin-assisted therapy for depression in Ontario Completed more than 6,000 treatments to date; expanded clinic footprint increasing capacity and greater access to network of mental health specialists Reported positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression   TORONTO, ONTARIO July 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its audited financial statements and management discussion and analysis for the year ended March 31, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing...

July 27, 2022

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

TORONTO, ONTARIO July 27, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for people living with depression and related mental health disorders, is pleased to announce the addition of Jason Wolkove, Chief Information Officer and Daniel Herrera, Vice President, Research & Development and Growth. These strategic hires bolster Braxia’s senior leadership team and its ability to drive growth and innovation. Both roles will be integral to executing the expansion of the Company’s clinical footprint, the rollout and expansion of novel ketamine and psilocybin therapy offerings, new special access programs, current and upcoming clinical trials, and the potential commercialization of future product development. Braxia’s new Chief Information Officer, Jason Wolkove, is a seasoned technology executive bringing more than 20 years of experience growing complex...

June 24, 2022

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

TORONTO, ONTARIO June 24, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York. Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address - Introduction to the State of Mental Healthcare – to kick off the conference on Monday, June 27 at 8:15 a.m. ET Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m. ET providing an overview of the Braxia’s business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression, while also expanding the...

June 15, 2022

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders

TORONTO, ONTARIO June 15, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada. Braxia’s group of clinics, led by top researchers in depression Dr. Roger McIntyre and Dr. Joshua Rosenblat – as determined by Expertscape – and now Braxia Health Kitchener-Waterloo, provide patients greater access to Braxia’s network of physicians, specialists and researchers delivering innovative, rapid acting treatments like intravenous (IV) and oral ketamine, and psilocybin for treatment resistant depression (TRD) and other mental health disorders.  Braxia Health clinics are also...

June 2, 2022

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

TORONTO, June 2, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and psilocybin treatments for depression and related mental health disorders, is pleased to announce positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression. The preliminary results were presented at the “From Research to Reality Conference” in Toronto, May 27-28, 2022. Positive Preliminary Results Highlights  Braxia Scientific’s ongoing multi-dose psilocybin trial effectively demonstrated the feasibility of Braxia’s proprietary psilocybin-assisted therapy protocol with high rates of recruitment and retention with adequate tolerability and safety. Clinically meaningful improvements in depression severity observed (as measured by the MADRS1) with complete analysis of antidepressant efficacy and...

May 20, 2022

Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of terminal medical illness or end of life distress. Approval marks Braxia’s first Special Access Program (SAP) approval for use of psilocybin in Ontario. To date Braxia’s experienced therapists have delivered psilocybin-assisted therapy treatments to 16 individuals with depression through its proprietary clinical trial commenced late 2021.   TORONTO, May 20, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders. Braxia Scientific is pleased to announce that Health Canada has approved the Company’s application to the Special Access Program (“SAP”) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in...

May 19, 2022

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

TORONTO, ONTARIO May 19, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida. Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright...

May 19, 2022

Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry

TORONTO, May 18, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) is pleased to announce that its CEO, Dr. Roger McIntyre has been invited to speak at the American Psychiatric Association Annual Meeting in New Orleans May 21, 2022. Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association. The first discussion titled - Ketamine and Esketamine for Treatment-Resistant Depression Synthesizing Scientific Data and Clinical Application will include a review of the International Guidelines on Ketamine and Implementation led by Dr. McIntyre, published in the American Journal of Psychiatry in May 2021.  The presentation will also cover real-world data (RWD) with respect to efficacy, safety, and tolerability of ketamine treatment in adults with mood disorders. The second discussion titled - Treatment Resistant Depression: Current and Future Pathways will be on...

April 13, 2022

Update - Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada

Agreements Subject to Court Approval TORONTO, April 13, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that it has reached an agreement in principle (the “US Settlement”) to settle claims alleged in a securities class action (“US Class Action”) pending against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021. The Company also announced it has signed a settlement agreement (the “Canadian Settlement”) to resolve a class action lawsuit (“Canadian Class Action”) that was filed in the British Columbia Supreme Court in May 2021 against the Company its CEO, certain of its former officers, a shareholder, and underwriters. The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class...

April 13, 2022

Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada

Agreements Subject to Court Approval TORONTO, April 13, 2022 - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that it has reached an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action ("US Class Action") pending against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021. The Company also announced it has signed a settlement agreement (the "Canadian Settlement") to resolve a class action lawsuit ("Canadian Class Action") that was filed in the British Columbia Supreme Court in May 2021 against the Company its CEO, certain of its former officers, a shareholder, and underwriters. The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class Action. The Canadian Settlement contemplates a cash payment...

April 1, 2022

Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6

TORONTO, April 1, 2022 - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce that CEO, Dr. Roger McIntyre and Chief Medical and Scientific Officer, Dr. Josh Rosenblatt have been invited to present at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford in Oxford, England. This meeting is one of the largest International Conferences on ketamine research, development, and clinical implementation. Braxia Scientific senior management will present on the following days, London, U.K. time. To access the live online webcasts please visit the conference website, or the links available below: Monday April 4, 2022 16:20 p.m. (London Time) Dr. Roger McIntyre will discuss Ketamine treatment for domain-based outcomes in persons with Treatment Resistant Depression Session abstract available here. 18:00 p.m. (London Time) Dr. Roger McIntyre will participate in a Debate: This House...

March 1, 2022

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada

  Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021- more than a dozen patients receive initial dose to date in first-ever Health Canada-approved, multi-dose psilocybin clinical trial in Canada Braxia Scientific funded psilocybin trial establishes psilocybin treatment framework for patients with Treatment Resistant Depression (TRD), provides patients immediate access to psychedelic treatments, and training for new therapists providing psilocybin-assisted therapy Clinics administer ~5,500 ketamine treatments to date across growing patient base in Canada   TORONTO, March 1, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal third-quarter results for the three-month period ending December 31, 2021. Complete financial statements along with related management discussion and analysis can be found...

January 31, 2022

Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

  TORONTO, ONTARIO January 31, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provided an update on the Company’s leading research role within the psychedelics industry. As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific’s team of researchers also continue to carry out multiple psychedelic-based clinical research trials, adding to the Company’s large and growing proprietary dataset critical to informing future drug development. To date, Braxia Scientific has compiled comprehensive health data from administering more than 5,200 ketamine treatments at its network of clinics. Additionally, Braxia Scientific’s researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia...

January 6, 2022

Braxia Scientific Announces CAD$3 Million Private Placement with Institutional Investors

  TORONTO, ONTARIO – Jan. 6, 2022 – Braxia Scientific Corp. (the “Company” or “Braxia”), (CSE: BRAX) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, is pleased to announce that it has entered into a securities purchase agreement with institutional investors for a private placement of its common shares (“Common Shares”) and warrants to purchase Common Shares (“Warrants”) for gross proceeds of approximately CAD$3 million (the “Private Placement”). Pursuant to the Private Placement, the Company will issue 30,000,000 Common Shares (or Common Share equivalents) and Warrants to purchase up to an aggregate of 30,000,000 Common Shares at a purchase price of CAD$0.10 per Common Share and associated Warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD$0.125 per Common Share for a...

December 14, 2021

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

  Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific’s subsidiary CRTCE clinic Trial establishes psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment   TORONTO, ONTARIO December 14th, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, has reached a milestone as the first Health Canada-approved multiple-dose psilocybin clinical trial which commenced with first patients dosed in November 2021. The trial, which is being sponsored by the Brain and Cognition Discovery Foundation, is being conducted at the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned Braxia subsidiary, and includes adults with treatment-resistant depression (TRD) as part of bipolar or...

December 13, 2021

A PATIENT'S Q&A

A PATIENT'S JOURNEY

December 13, 2021
November 29, 2021

Second Quarter 2022 Financial Results; Corporate Update

Braxia Scientific Reports Second Quarter 2022 Financial Results and Provides Corporate Update   Expanded clinical infrastructure to support a growing portfolio of clinical trials of novel interventions and for drug discovery; 14 registered clinical trials in depression, led by Company CEO and Chief Medical and Scientific Officer, completed or in process Excellent progress on only psilocybin trial in Canada actively recruiting study participants to receive psilocybin-assisted therapy Clinical footprint in Canada has administered ~4,900 ketamine treatments to date; focus on expansion opportunities in the U.S. and Europe TORONTO, ONTARIO Nov. 29, 2021 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal second-quarter results for the three-month period ending September 30,...

November 8, 2021

Advisory Board of KetaMD

Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD TORONTO, ONTARIO Nov. 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, is joining KetaMD as an adviser. KetaMD, currently in beta, is a telemedicine platform in development that aims to provide affordable, potentially life-changing at-home medical ketamine treatments guided by registered nurses over telemedicine. Dr. McIntyre is a world-renowned expert in the treatment of depression and has contributed extensively to clinical practice guidelines for ketamine. He has been involved in nearly 750 published research endeavours centered around the treatment of mental health disorders. Dr. McIntrye is also the lead author...

November 8, 2021

Keynote at Wonderland: Miami

Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami TORONTO, Ontario Nov. 8, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference. The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space. Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline...